Inhibikase Therapeutics

Youtube Subscribe

Open: 1.0 Close: 0.98 Change: -0.02

The stock market through the eyes of an AI: Inhibikase Therapeutics Stock.

The game is changing. There is a new strategy to evaluate Inhibikase Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Inhibikase Therapeutics are: Inhibikase, Therapeutics, report, disease, Analysts, estimate, earnings, …

Concept Map

Semantic Network

Stock Summary

Inhibikase Therapeutics, Inc. develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor. IkT.

Today's Summary

Analysts estimate Inhibikase Therapeutics will report an earnings per share (EPS) of $-1.19. Shares of IKT were trading at $1.0 as of November 10. Inhibikase Therapeutics reports third quarter financial results and highlights recent period activity. Company is developing protein kinase inhibitor therapeutics to modify the course of Parkinsons disease (PD) and other diseases.

Today's News

Analysts estimate Inhibikase Therapeutics will report an earnings per share (EPS) of $-1.19. Shares of IKT were trading at $1.0 as of November 10. Inhibikase Therapeutics reports third quarter financial results and highlights recent period activity. Company is developing protein kinase inhibitor therapeutics to modify the course of Parkinsons disease (PD) and other diseases.

Stock Profile

"Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia."

Keywords

This document will help you to evaluate Inhibikase Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Inhibikase Therapeutics are: Inhibikase, Therapeutics, report, disease, Analysts, estimate, earnings, and the most common words in the summary are: inc, therapeutic, health, university, inhibikase, llc, stock, . One of the sentences in the summary was: Inhibikase Therapeutics reports third quarter financial results and highlights recent period activity. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #inc #therapeutic #health #university #inhibikase #llc #stock.

Read more →

Youtube Subscribe

---